An overwhelming majority of the audience at an RSNA special focus session Thursday voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
An overwhelming majority of the audience at an RSNA special focus session Thursday voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
When moderator Dr. Peter N. Burns asked those in the 200-plus crowd to raise their hands if they thought the plug should not be pulled on ultrasound contrast, not more than a dozen physicians kept theirs down. When Burns asked to see the hands of those who thought contrast should be let go, only one went up.
A panel composed of Drs. Burns and Stephanie R. Wilson from Canada, Luigi Solbiati from Italy, and Myron A. Pozniak from Madison, WI, discussed the regulatory approval status for contrast-enhanced sonography around the world, its clinical applications, and the arguments in favor of and against the technique.
After the panel discussion and the symbolic voting, members of the audience shared commentaries. Most agreed that the technique is useful and valuable in multiple imaging subspecialties: musculoskeletal, ob/gyn, cardiovascular, and interventional radiology, to name only a few. They also agreed, however, that the reimbursement landscape in the U.S. overwhelmingly favors CT and MR imaging over sonography, which is still considered a time-consuming and operator-dependent modality.
Many said the choice is inevitable. But it could also be harmful to radiology.
"The FDA does not get any benefit from saying 'yes' and having a complication or something negative occur. And there is no cost to them to saying 'no.' The constituency for this is outside radiology," an audience member said. "But then everybody else will end up doing ultrasound and in the future radiologists will be relegated to the sidelines by other subspecialists, who will be doing diagnostic studies using contrast ultrasound."
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.